Skip to main content
SpringerLink
Log in

Psychopharmacology in Bariatric Surgery Patients

  • Chapter
  • First Online:
Psychiatric Care in Severe Obesity

Abstract

Many bariatric surgery patients use psychiatric medications, and this number is expected to increase in coming years, and to include an increasing variety of medications. Thus, clinicians must be familiar with managing psychotropic medications in the perioperative bariatric surgery period. Bariatric surgery can generate a number of pharmacokinetic changes, primarily in medication absorption, but in other areas as well. The degree and clinical impact of these changes is variable, dependent on a complex interplay of patient, medication, and surgical factors. This chapter draws on evidence from the literature and expert consensus to describe possible bariatric surgery-related pharmacokinetic changes for the major classes of psychiatric drugs, and discusses management strategies to address these issues.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Kalarchian MA, Marcus MD, Levine MD, Courcoulas AP, Pilkonis PA, Ringham RM, et al. Psychiatric disorders among bariatric surgery candidates: relationship to obesity and functional health status. Am J Psychiatry. 2007;164:328–34. doi:10.1176/ajp.2007.164.2.328. Quiz 374.

    Article  PubMed  Google Scholar 

  2. Mitchell JE, King WC, Chen J-Y, Devlin MJ, Flum D, Garcia L, et al. Course of depressive symptoms and treatment in the longitudinal assessment of bariatric surgery (LABS-2) study. Obesity (Silver Spring). 2014;22:1799–806. doi:10.1002/oby.20738.

    Article  Google Scholar 

  3. Roerig JL, Steffen K. Psychopharmacology and bariatric surgery. Eur Eat Disord Rev. 2015;23:463–9. doi:10.1002/erv.2396.

    Article  PubMed  Google Scholar 

  4. Katzung B. Basic and clinical pharmacology. 10th ed. New York: McGraw-Hill; 2007.

    Google Scholar 

  5. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11:41–50. doi:10.1111/j.1467-789X.2009.00614.x.

    Article  CAS  PubMed  Google Scholar 

  6. Macgregor AM, Boggs L. Drug distribution in obesity and following bariatric surgery: a literature review. Obes Surg. 1996;6:17–27. doi:10.1381/096089296765557222.

    Article  PubMed  Google Scholar 

  7. Alexander JK. Obesity and cardiac performance. Am J Cardiol. 1964;14:860–5.

    Article  CAS  PubMed  Google Scholar 

  8. de Divitiis O, Fazio S, Petitto M, Maddalena G, Contaldo F, Mancini M. Obesity and cardiac function. Circulation. 1981;64:477–82.

    Article  PubMed  Google Scholar 

  9. Blouin RA, Kolpek JH, Mann HJ. Influence of obesity on drug disposition. Clin Pharm. 1987;6:706–14.

    CAS  PubMed  Google Scholar 

  10. Shargel L, Wu-Pong S, Yu A. Applied biopharmaceutics & pharmacokinetics. 6th ed. New York: McGraw-Hill Education; 2012.

    Google Scholar 

  11. Yska JP, van der Linde S, Tapper VV, Apers JA, Emous M, Totté ER, et al. Influence of bariatric surgery on the use and pharmacokinetics of some major drug classes. Obes Surg. 2013;23:819–25. doi:10.1007/s11695-013-0882-6.

    Article  PubMed  Google Scholar 

  12. Marzinke MA, Petrides AK, Steele K, Schweitzer MA, Magnuson TH, Reinblatt SP, et al. Decreased escitalopram concentrations post-Roux-en-Y gastric bypass surgery. Ther Drug Monit. 2015;37:408–12. doi:10.1097/FTD.0000000000000146.

    Article  CAS  PubMed  Google Scholar 

  13. Hamad GG, Helsel JC, Perel JM, Kozak GM, McShea MC, Hughes C, et al. The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry. 2012;169:256–63. doi:10.1176/appi.ajp.2011.11050719.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Roerig JL, Steffen KJ, Zimmerman C, Mitchell JE, Crosby RD, Cao L. A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. J Clin Psychopharmacol. 2013;33:479–84. doi:10.1097/JCP.0b013e3182905ffb.

    Article  CAS  PubMed  Google Scholar 

  15. Roerig JL, Steffen K, Zimmerman C, Mitchell JE, Crosby RD, Cao L. Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis. 2012;8:62–6. doi:10.1016/j.soard.2010.12.003.

    Article  PubMed  Google Scholar 

  16. Seaman JS, Bowers SP, Dixon P, Schindler L. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics. 2005;46:250–3. doi:10.1176/appi.psy.46.3.250.

    Article  PubMed  Google Scholar 

  17. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44:77–87.

    Article  CAS  PubMed  Google Scholar 

  18. Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci. 2000;25:255–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Bingham K, Hawa R, Sockalingam S. SSRI discontinuation syndrome following bariatric surgery: a case report and focused literature review. Psychosomatics. 2014;55:692–7. doi:10.1016/j.psym.2014.07.003.

    Article  PubMed  Google Scholar 

  20. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282:1737–44.

    Article  CAS  PubMed  Google Scholar 

  21. Cassin S, Sockalingam S, Hawa R, Wnuk S, Royal S, Taube-Schiff M, et al. Psychometric properties of the Patient Health Questionnaire (PHQ-9) as a depression screening tool for bariatric surgery candidates. Psychosomatics. 2013;54:352–8. doi:10.1016/j.psym.2012.08.010.

    Article  PubMed  Google Scholar 

  22. McIntyre RS, Konarski JZ, Wilkins K, Soczynska JK, Kennedy SH. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51:274–80.

    PubMed  Google Scholar 

  23. Walsh K, Volling J. Lithium toxicity following Roux-en-Y gastric bypass. Bariatr Surg Pract Patient Care. 2014;9:77–80.

    Article  Google Scholar 

  24. Nykiel J, Carino G, Levinson A. Lithium toxicity in the context of recent gastric bypass surgery. Case Vignettes Clin Care II Respir Crit Care Med Abstr Issue. 2014;189:A6203.

    Google Scholar 

  25. Tripp AC. Lithium toxicity after Roux-en-Y gastric bypass surgery. J Clin Psychopharmacol. 2011;31:261–2. doi:10.1097/JCP.0b013e318210b203.

    Article  PubMed  Google Scholar 

  26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35.

    Article  CAS  PubMed  Google Scholar 

  28. Keck PE, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry. 2002;63 Suppl 4:3–11.

    CAS  PubMed  Google Scholar 

  29. Kaltsounis J, De Leon OA. Intravenous valproate treatment of severe manic symptoms after gastric bypass surgery: a case report. Psychosomatics. 2000;41:454–6. doi:10.1176/appi.psy.41.5.454.

    Article  CAS  PubMed  Google Scholar 

  30. Semion K, Dorsey J, Bourgeois J. Intravenous valproate use in bipolar II disorder after gastric bypass surgery. J Neuropsychiatry Clin Neurosci. 2005;17:427–9. doi:10.1176/jnp.17.3.427-a.

    Article  PubMed  Google Scholar 

  31. Koutsavlis I, Muayed L. Dose-dependent carbamazepine-induced agranulocytosis following bariatric surgery (Sleeve Gastrectomy): a possible mechanism. Bariatr Surg Pract Patient Care. 2014;10:130–4.

    Article  Google Scholar 

  32. Pournaras DJ, Footitt D, Mahon D, Welbourn R. Reduced phenytoin levels in an epileptic patient following Roux-En-Y gastric bypass for obesity. Obes Surg. 2011;21:684–5. doi:10.1007/s11695-010-0107-1.

    Article  PubMed  Google Scholar 

  33. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–87. doi:10.1001/archpsyc.63.10.1079.

    Article  CAS  PubMed  Google Scholar 

  34. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23. doi:10.1056/NEJMoa051688.

    Article  CAS  PubMed  Google Scholar 

  35. Maher AR, Maglione M, Bagley S, Suttorp M, Hu J-H, Ewing B, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA. 2011;306:1359–69. doi:10.1001/jama.2011.1360.

    Article  CAS  PubMed  Google Scholar 

  36. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–96. doi:10.1176/ajp.156.11.1686.

    CAS  PubMed  Google Scholar 

  37. Javaid JI. Clinical pharmacokinetics of antipsychotics. J Clin Pharmacol. 1994;34:286–95.

    Article  CAS  PubMed  Google Scholar 

  38. Fuller AK, Tingle D, DeVane CL, Scott JA, Stewart RB. Haloperidol pharmacokinetics following gastric bypass surgery. J Clin Psychopharmacol. 1986;6:376–8.

    CAS  PubMed  Google Scholar 

  39. Hamoui N, Kingsbury S, Anthone GJ, Crookes PF. Surgical treatment of morbid obesity in schizophrenic patients. Obes Surg. 2004;14:349–52. doi:10.1381/096089204322917873.

    Article  PubMed  Google Scholar 

  40. Brietzke E, Lafer B. Long-acting injectable risperidone in a bipolar patient submitted to bariatric surgery and intolerant to conventional mood stabilizers. Psychiatry Clin Neurosci. 2011;65:205. doi:10.1111/j.1440-1819.2010.02175.x.

    Article  PubMed  Google Scholar 

  41. Gandelman K, Alderman JA, Glue P, Lombardo I, LaBadie RR, Versavel M, et al. The impact of calories and fat content of meals on oral ziprasidone absorption: a randomized, open-label, crossover trial. J Clin Psychiatry. 2009;70:58–62.

    Article  CAS  PubMed  Google Scholar 

  42. Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther. 2009;26:739–48. doi:10.1007/s12325-009-0055-0.

    Article  CAS  PubMed  Google Scholar 

  43. Zeldox product monograph. 2014.

    Google Scholar 

  44. Preskorn S, Ereshefsky L, Chiu Y-Y, Poola N, Loebel A. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol. 2013;28:495–505. doi:10.1002/hup.2338.

    Article  CAS  PubMed  Google Scholar 

  45. Bartlett JA, van der Voort Maarschalk K. Understanding the oral mucosal absorption and resulting clinical pharmacokinetics of asenapine. AAPS PharmSciTech. 2012;13:1110–5. doi:10.1208/s12249-012-9839-7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Tabaac BJ, Tabaac V. Pica patient, status post gastric bypass, improves with change in medication regimen. Ther Adv Psychopharmacol. 2015;5:38–42. doi:10.1177/2045125314561221.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Saphris prescribing information. 2015.

    Google Scholar 

  48. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses. 2012;6:134–44. doi:10.3371/CSRP.6.3.5.

    Article  PubMed  Google Scholar 

  49. Young CR, Bowers MB, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull. 1998;24:381–90.

    Article  CAS  PubMed  Google Scholar 

  50. Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry. 2008;69:759–68.

    Article  CAS  PubMed  Google Scholar 

  51. Afshar S, Kelly SB, Seymour K, Woodcock S, Werner A-D, Mathers JC. The effects of bariatric procedures on bowel habit. Obes Surg. 2016;26:2348–2354. doi:10.1007/s11695-016-2100-9.

  52. Clozaril product monograph. 2015.

    Google Scholar 

  53. Stark A, Scott J. A review of the use of clozapine levels to guide treatment and determine cause of death. Aust N Z J Psychiatry. 2012;46:816–25. doi:10.1177/0004867412438871.

    Article  PubMed  Google Scholar 

  54. Zhou S-F, Yang L-P, Zhou Z-W, Liu Y-H, Chan E. Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009;11:481–94. doi:10.1208/s12248-009-9127-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26:733–59. doi:10.2165/11634500-000000000-00000.

    Article  PubMed  Google Scholar 

  56. Klemp M, Tvete IF, Skomedal T, Gaasemyr J, Natvig B, Aursnes I. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. J Clin Psychopharmacol. 2011;31:698–704. doi:10.1097/JCP.0b013e31823657d9.

    Article  CAS  PubMed  Google Scholar 

  57. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62. doi:10.1016/S0140-6736(13)60733-3.

    Article  CAS  PubMed  Google Scholar 

  58. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601.

    Article  Google Scholar 

  59. Clerc GE, Ruimy P, Verdeau-Pallès J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol. 1994;9:139–43.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

The authors wish to thank Sassha Orser RPh., ACPR for her assistance in preparing this chapter.

Author information

Authors and Affiliations

  1. University Health Network, 399 Bathurst Street, Toronto, ON, Canada, M5T 2S8

    Kathleen S. Bingham

  2. Toronto Western Hospital Bariatric Surgery Program, University Health Network, Toronto, ON, Canada

    Richard Yanofsky

  3. Department of Psychiatry, University of Toronto, Toronto, ON, Canada

    Richard Yanofsky

Authors
  1. Kathleen S. Bingham
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Yanofsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Yanofsky .

Editor information

Editors and Affiliations

  1. Toronto Western Hospital Bariatric Surgery Program, Centre for Mental Health, University Health Network, Toronto, Ontario, Canada

    Sanjeev Sockalingam

  2. Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada

    Raed Hawa

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Bingham, K.S., Yanofsky, R. (2017). Psychopharmacology in Bariatric Surgery Patients. In: Sockalingam, S., Hawa, R. (eds) Psychiatric Care in Severe Obesity. Springer, Cham. https://doi.org/10.1007/978-3-319-42536-8_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42536-8_23

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42534-4

  • Online ISBN: 978-3-319-42536-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation